药物警戒数据库中间质性肺病分析:编码挑战与解读偏倚更新
本研究分析了VigiBase中五种已知肺毒性药物相关间质性肺病(ILD)的MedDRA编码演变,并系统综述22项药物警戒研究。发现宽泛SMQ「ILD」中「ILD」PT年均占比不足40%,编码随时间和国家变化;仅50%研究使用PT查询,27%进行敏感性分析,无研究讨论编码演变对可靠性的影响。
要点
- 宽泛SMQ「ILD」中「ILD」PT年均占比不足40%,编码异质性高。
- 编码术语随时间和国家变化,如2019年后出现「免疫介导性肺病」。
- 仅27%的药物警戒研究进行敏感性分析,无研究评估编码演变影响。
核心结论
- MedDRA编码的显著变异性可能影响药物安全性分析的可靠性,药物警戒研究对查询标准的相关性评估不足。
研究设计与样本
- 描述VigiBase中五种已知肺毒性药物(胺碘酮、甲氨蝶呤、纳武利尤单抗、帕博利珠单抗、依维莫司)相关ILD的MedDRA PT(按报告年份2000-2024、国家、报告者类型),并进行系统文献综述识别使用不一致性分析检测药物诱导ILD报告信号的药物警戒研究。
主要发现
- 宽泛SMQ「ILD」中「ILD」PT年均占比不足40%。
- 观察到术语演变(如2019年后出现「免疫介导性肺病」)和国家偏好(法国/日本 vs 美国/英国/德国)。
- 22项可获取的综述研究中,50%使用基于PT的查询,仅27%进行敏感性分析,无研究讨论MedDRA编码演变对分析可靠性的影响。
关键数值与推荐
- 宽泛SMQ「ILD」中「ILD」PT年均占比不足40%。
- 22项研究中50%使用基于PT的查询,27%进行敏感性分析,0%讨论编码演变影响。
临床怎么用
- 在药物警戒数据库分析中应评估查询标准的相关性,考虑MedDRA编码演变和国家差异对信号检测的影响,并开展敏感性分析。
局限性
- 仅纳入22项可获取的综述研究,可能未全面覆盖所有相关药物警戒研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection. This study aimed to investigate interpretation biases related to ILD coding in PV databases. METHODS: MedDRA Preferred Terms (PT) included in the broad Standardized MedDRA Query (SMQ) 'ILD' for the top five known pneumotoxic drugs was described in VigiBase by reporting year (2000-2024), country, and reporter type. Then, a systematic literature review was conducted to identify PV studies using disproportionality analyses to detect drug-induced ILD reporting signals, assessing query strategies, analysis units, and bias consideration. RESULTS: The most frequently implicated known pneumotoxic drugs were amiodarone, methotrexate, nivolumab, pembrolizumab, and everolimus. On average per year, the PTs 'ILD' represented <40% of all PTs in the broad SMQ 'ILD'. Terminology evolution (e.g., emergence of 'immune-mediated lung disease' after 2019) and national preferences (France/Japan vs. USA/UK/Germany) were observed. Among 22 reviewed accessible studies, 50% used PT-based queries, only 27% performed sensitivity analyses, and none discussed the impact of MedDRA coding evolution on analysis reliability. DISCUSSION/CONCLUSION: Our analysis highlights the substantial variability in MedDRA coding that may affect the reliability of drug safety analyses. Moreover, studies conducted on PV databases do not sufficiently assess the relevance of query criteria and their impact on the results. We propose a few practical recommendations.
引用
- Freppel R, Benis A, Bonniaud P, et al. Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases-An update. Br J Clin Pharmacol. 2026. PMID: 41693128. doi:10.1002/bcp.70483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。